Shopping Cart

Your shopping cart is currently empty

SARS-CoV-2-IN-14

Name: SARS-CoV-2-IN-14
Brand: TargetMol
SKU: T60538
Price: 30 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T60538Cas No. 22203-98-1

Alias 3',5-Dichlorosalicylanilide

SARS-CoV-2-IN-14 is a potent and oral inhibitor of SARS-CoV-2 (IC50:0.39 μM), which is an analogue of niclosamide. SARS-CoV-2-IN-14 was more stable than niclosamide in the determination of human plasma and liver S9 enzyme. Oral administration of SARS-CoV-2-IN-14 can improve its bioavailability and half-life.

SARS-CoV-2-IN-14

Copy Product Info

😃Good

Purity: 99.78%

Catalog No. T60538Alias 3',5-DichlorosalicylanilideCas No. 22203-98-1

Pack Size	Price	USA Warehouse	Global Warehouse
10 mg	$38	In Stock	In Stock
25 mg	$59	In Stock	In Stock
50 mg	$92	In Stock	In Stock
100 mg	$137	In Stock	In Stock
200 mg	$198	-	In Stock
1 mL x 10 mM (in DMSO)	$30	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.78%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

SARS-CoV-2-IN-14 AI Summary

SARS-CoV-2-IN-14 exhibits a range of bioactivities, including significant antimycobacterial effects, antiviral properties, and inhibition of specific biochemical pathways and receptors. It shows activity against various Mycobacterium strains, such as Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium kansasii, with MIC values ranging from 4000.0 nM to 16000.0 nM. In HEK293 cells, it inhibits the Wnt/beta-catenin pathway with an IC50 of 1650.0 nM. Moreover, it reduces the activity of Cryptosporidium hominis TS-DHFR enzyme by 54% at 500 uM. In terms of receptor antagonism, SARS-CoV-2-IN-14 inhibits ATP-induced calcium influx at the human P2X1 receptor (P2X2/P2X1 chimera) with an IC50 of 75.6 nM and 64.0% inhibition at 10 uM pre-incubation, and shows moderate inhibition at the P2X4 receptor with an IC50 of 135.0 nM. It does not significantly affect P2X2, P2X3, or P2X7 receptors, with IC50 values above 10000.0 nM. The compound demonstrates antiviral activity against SARS-CoV-2 in African Green monkey Vero cells with an IC50 of 390.0 nM and cytotoxicity in Vero E6 cells with a CC50 of 2460.0 nM, giving a selectivity ratio of 6.3. It has a permeability of 8.6 x 10^-6 cm/s, low water solubility (<1.0 ug/mL), 71.0% stability in human plasma, and 33.0% metabolic stability in human liver microsomes. Additionally, it exhibits cytotoxicity against Vero E6 cells preincubated for 2 hours, followed by SARS-CoV-2 addition, with a CC50 of 100000.0 nM..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	SARS-CoV-2-IN-14 is a potent and oral inhibitor of SARS-CoV-2 (IC50:0.39 μM), which is an analogue of niclosamide. SARS-CoV-2-IN-14 was more stable than niclosamide in the determination of human plasma and liver S9 enzyme. Oral administration of SARS-CoV-2-IN-14 can improve its bioavailability and half-life.
Targets&IC50	SARS-CoV-2:0.39 μM
Synonyms	3',5-Dichlorosalicylanilide

Chemical Properties

Molecular Weight	282.12
Formula	C₁₃H₉Cl₂NO₂
Cas No.	22203-98-1
Smiles	C(NC1=CC(Cl)=CC=C1)(=O)C2=C(O)C=CC(Cl)=C2

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 9 mg/mL (31.9 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	3.5446 mL	17.7230 mL	35.4459 mL	177.2295 mL
5 mM	0.7089 mL	3.5446 mL	7.0892 mL	35.4459 mL
10 mM	0.3545 mL	1.7723 mL	3.5446 mL	17.7230 mL
20 mM	0.1772 mL	0.8861 mL	1.7723 mL	8.8615 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc